Christine Beeton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3592885/publications.pdf

Version: 2024-02-01

77 papers	5,019 citations	117453 34 h-index	91712 69 g-index
82 all docs	82 docs citations	82 times ranked	4850 citing authors

#	Article	IF	Citations
1	Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17414-17419.	3.3	470
2	K+ channels as targets for specific immunomodulation. Trends in Pharmacological Sciences, 2004, 25, 280-289.	4.0	404
3	Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation, 2018, 138, 2227-2242.	1.6	376
4	The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. Journal of Clinical Investigation, 2003, 111, 1703-1713.	3.9	368
5	Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases. Molecular Pharmacology, 2005, 67, 1369-1381.	1.0	232
6	Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon, 2012, 59, 529-546.	0.8	203
7	Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block. Immunity, 2008, 29, 602-614.	6.6	197
8	Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation. Journal of Immunology, 2001, 166, 936-944.	0.4	180
9	The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11094-11099.	3.3	172
10	Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nature Communications, 2011, 2, 334.	5.8	142
11	AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. Molecular Therapy, 2020, 28, 1432-1441.	3.7	140
12	Kv1.3-Blocking 5-Phenylalkoxypsoralens: A New Class of Immunomodulators. Molecular Pharmacology, 2004, 65, 1364-1374.	1.0	126
13	Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 642-653.	1.3	105
14	Potassium Channels, Memory T Cells, and Multiple Sclerosis. Neuroscientist, 2005, 11, 550-562.	2.6	96
15	Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases. Inflammation and Allergy: Drug Targets, 2011, 10, 313-321.	1.8	83
16	Vm24, a Natural Immunosuppressive Peptide, Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells. Molecular Pharmacology, 2012, 82, 372-382.	1.0	83
17	A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-regulation in Chronically Activated T Lymphocytes. Journal of Biological Chemistry, 2003, 278, 9928-9937.	1.6	80
18	Detection of Functional Matrix Metalloproteinases by Zymography. Journal of Visualized Experiments, 2010, , .	0.2	77

#	Article	IF	Citations
19	Kv1.3 channelâ€blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB Journal, 2014, 28, 3952-3964.	0.2	76
20	Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. International Immunopharmacology, 2014, 22, 427-443.	1.7	74
21	A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Scientific Reports, 2014, 4, 4509.	1.6	73
22	Potassium channels as therapeutic targets for autoimmune disorders. Current Opinion in Drug Discovery & Development, 2003, 6, 640-7.	1.9	60
23	A Potent and Selective Peptide Blocker of the Kv1.3 Channel: Prediction from Free-Energy Simulations and Experimental Confirmation. PLoS ONE, 2013, 8, e78712.	1.1	58
24	Blocking KV1.3 Channels Inhibits Th2 Lymphocyte Function and Treats a Rat Model of Asthma. Journal of Biological Chemistry, 2014, 289, 12623-12632.	1.6	58
25	Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK. Marine Drugs, 2015, 13, 529-542.	2.2	55
26	The D-Diastereomer of ShK Toxin Selectively Blocks Voltage-gated K+ Channels and Inhibits T Lymphocyte Proliferation. Journal of Biological Chemistry, 2008, 283, 988-997.	1.6	54
27	Evidence for Domain-specific Recognition of SK and Kv Channels by MTX and HsTx1 Scorpion Toxins. Journal of Biological Chemistry, 2004, 279, 55690-55696.	1.6	51
28	Ion channels and anti-cancer immunity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130106.	1.8	50
29	Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clinical Immunology, 2017, 180, 45-57.	1.4	50
30	Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocytes. PLoS ONE, 2013, 8, e76740.	1.1	45
31	KCa1.1 Potassium Channels Regulate Key Proinflammatory and Invasive Properties of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. Journal of Biological Chemistry, 2012, 287, 4014-4022.	1.6	43
32	Ca2+ permeation and/or binding to CaV1.1 fine-tunes skeletal muscle Ca2+ signaling to sustain muscle function. Skeletal Muscle, 2015, 5, 4.	1.9	43
33	Inhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response. Neuron, 2019, 104, 665-679.e8.	3.8	43
34	A Câ€terminally amidated analogue of ShK is a potent and selective blocker of the voltageâ€gated potassium channel Kv1.3. FEBS Letters, 2012, 586, 3996-4001.	1.3	41
35	Detection of Matrix Metalloproteinases by Zymography. Methods in Molecular Biology, 2017, 1579, 231-244.	0.4	35
36	Differences in ion channel phenotype and function between humans and animal models. Frontiers in Bioscience - Landmark, 2018, 23, 43-64.	3.0	34

#	Article	IF	Citations
37	The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clinical Immunology, 2015, 158, 183-192.	1.4	33
38	Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. Scientific Reports, 2016, 6, 33808.	1.6	32
39	Drawing Blood from Rats through the Saphenous Vein and by Cardiac Puncture. Journal of Visualized Experiments, 2007, , 266.	0.2	30
40	KCa1.1 Inhibition Attenuates Fibroblastâ€like Synoviocyte Invasiveness and Ameliorates Disease in Rat Models of Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 96-106.	2.9	29
41	Nâ€terminally extended analogues of the K⁺ channel toxin from StichodactylaÂhelianthus as potent and selective blockers of the voltageâ€gated potassium channel Kv1.3. FEBS Journal, 2015, 282, 2247-2259.	2.2	26
42	Recombinant Expression of Margatoxin and Agitoxin-2 in Pichia pastoris: An Efficient Method for Production of KV1.3 Channel Blockers. PLoS ONE, 2012, 7, e52965.	1.1	24
43	Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon, 2012, 60, 840-850.	0.8	23
44	KCa1.1 channels regulate Î²₁â€integrin function and cell adhesion in rheumatoid arthritis fibroblastâ€like synoviocytes. FASEB Journal, 2017, 31, 3309-3320.	0.2	22
45	The impact of the fourth disulfide bridge in scorpion toxins of the Î±-KTx6 subfamily. Proteins: Structure, Function and Bioinformatics, 2005, 61, 1010-1023.	1.5	21
46	Different expression of Î² subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes. Arthritis Research and Therapy, 2016, 18, 103.	1.6	21
47	Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 227-236.	1.3	20
48	Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death and Disease, 2016, 7, e2426-e2426.	2.7	19
49	KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 6.	1.6	19
50	Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis. Journal of Visualized Experiments, 2007, , 224.	0.2	18
51	Modulation of Lymphocyte Potassium Channel K_V1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. ACS Pharmacology and Translational Science, 2020, 3, 720-736.	2.5	18
52	Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE. Journal of Visualized Experiments, 2007, , 527.	0.2	16
53	Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Scientific Reports, 2017, 7, 3756.	1.6	15
54	Quantitative Measurement of GLUT4 Translocation to the Plasma Membrane by Flow Cytometry. Journal of Visualized Experiments, 2010, , .	0.2	14

#	Article	IF	Citations
55	Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats. Journal of Visualized Experiments, 2007, , 237.	0.2	13
56	Induction and Monitoring of Adoptive Delayed-Type Hypersensitivity in Rats. Journal of Visualized Experiments, 2007, , .	0.2	13
57	Preparing T Cell Growth Factor from Rat Splenocytes. Journal of Visualized Experiments, 2007, , 402.	0.2	13
58	Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Scientific Reports, 2015, 5, 15776.	1.6	12
59	Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease. American Journal of Translational Research (discontinued), 2014, 6, 188-205.	0.0	11
60	Targets and Therapeutic Properties. , 2013, , 473-482.		10
61	Myelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro. NeuroReport, 2003, 14, 317-320.	0.6	8
62	KCa1.1 channels as therapeutic targets for rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 2017, 21, 1077-1081.	1.5	8
63	CHAPTER 10. Case Study 2: Transforming a Toxin into a Therapeutic: theÂSea Anemone Potassium Channel Blocker ShK Toxin for Treatment of Autoimmune Diseases. RSC Drug Discovery Series, 2015, , 255-274.	0.2	7
64	Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury. Journal of Neurotrauma, 2017, 34, 1175-1186.	1.7	7
65	Enrichment of NK Cells from Human Blood with the RosetteSep Kit from StemCell Technologies. Journal of Visualized Experiments, 2007, , 326.	0.2	6
66	Characterization of a novel MRâ€detectable nanoantioxidant that mitigates the recall immune response. NMR in Biomedicine, 2016, 29, 1436-1444.	1.6	5
67	Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts. Scientific Reports, 2022, 12, 2847.	1.6	4
68	Targets and Therapeutic Properties of Venom Peptides. , 2006, , 403-414.		3
69	Antioxidant Carbon Nanoparticles Inhibit Fibroblast-Like Synoviocyte Invasiveness and Reduce Disease Severity in a Rat Model of Rheumatoid Arthritis. Antioxidants, 2020, 9, 1005.	2.2	3
70	Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis. Frontiers in Pharmacology, 2021, 12, 714841.	1.6	3
71	Imaging Effector Memory T cells in the Ear After Induction of Adoptive DTH. Journal of Visualized Experiments, 2008, , .	0.2	2
72	The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. Journal of Clinical Investigation, 2003, 112, 298-298.	3.9	1

#	Article	IF	Citations
73	Live imaging of effector memory T cells at a site of inflammation â€“a Kv1.3 blocker suppresses T cell motility. FASEB Journal, 2007, 21, A770.	0.2	0
74	Potassium channels on natural killer cells in the presence of breast carcinoma cells. FASEB Journal, 2012, 26, 966.4.	0.2	0
75	The role of SODâ€2 in a mouse model of multiple sclerosis. FASEB Journal, 2012, 26, 136.11.	0.2	0
76	Targeting Potassium Channels On Fibroblastâ€like Synoviocytes For The Treatment Of Pristane Induced Arthritis In A Rat Model. FASEB Journal, 2012, 26, 1119.6.	0.2	0
77	Discovery on Target 2007--CHI's Fifth Annual Conference. Ion channels. IDrugs: the Investigational Drugs Journal, 2007, 10, 851-4.	0.7	0